Regeneron Pharmaceuticals, Inc. (REGN)
951.19
-8.22
(-0.86%)
USD |
NASDAQ |
Nov 12, 16:00
953.91
+2.72
(+0.29%)
After-Hours: 20:00
Regeneron Pharmaceuticals Net Income (Quarterly) : 1.949B for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.949B |
| June 30, 2026 | 1.297B |
| March 31, 2026 | 727.20M |
| December 31, 2025 | 844.60M |
| September 30, 2025 | 1.46B |
| June 30, 2025 | 1.392B |
| March 31, 2025 | 808.70M |
| December 31, 2024 | 917.70M |
| September 30, 2024 | 1.341B |
| June 30, 2024 | 1.432B |
| March 31, 2024 | 722.00M |
| December 31, 2023 | 1.160B |
| September 30, 2023 | 1.008B |
| June 30, 2023 | 968.40M |
| March 31, 2023 | 817.80M |
| December 31, 2022 | 1.197B |
| September 30, 2022 | 1.316B |
| June 30, 2022 | 852.10M |
| March 31, 2022 | 973.50M |
| December 31, 2021 | 2.229B |
| September 30, 2021 | 1.632B |
| June 30, 2021 | 3.099B |
| March 31, 2021 | 1.115B |
| December 31, 2020 | 1.149B |
| September 30, 2020 | 842.10M |
| Date | Value |
|---|---|
| June 30, 2020 | 897.30M |
| March 31, 2020 | 624.60M |
| December 31, 2019 | 792.00M |
| September 30, 2019 | 669.60M |
| June 30, 2019 | 193.10M |
| March 31, 2019 | 461.10M |
| December 31, 2018 | 820.40M |
| September 30, 2018 | 594.66M |
| June 30, 2018 | 551.41M |
| March 31, 2018 | 477.98M |
| December 31, 2017 | 173.52M |
| September 30, 2017 | 388.32M |
| June 30, 2017 | 387.74M |
| March 31, 2017 | 248.93M |
| December 31, 2016 | 253.12M |
| September 30, 2016 | 264.80M |
| June 30, 2016 | 196.22M |
| March 31, 2016 | 181.38M |
| December 31, 2015 | 154.99M |
| September 30, 2015 | 210.40M |
| June 30, 2015 | 194.64M |
| March 31, 2015 | 76.02M |
| December 31, 2014 | 110.18M |
| September 30, 2014 | 79.72M |
| June 30, 2014 | 92.74M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 2.429B |
| AbbVie, Inc. | 4.207B |
| Vertex Pharmaceuticals, Inc. | 653.60M |
| Amgen, Inc. | 3.864B |
| Biogen, Inc. | -20.60M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 5.116B |
| Total Expenses (Quarterly) | 3.167B |
| EPS Diluted (Quarterly) | 18.45 |
| Enterprise Value | 91.75B |
| Gross Profit Margin (Quarterly) | 86.42% |
| Profit Margin (Quarterly) | 38.09% |
| Earnings Yield | 4.76% |
| Operating Earnings Yield | 5.06% |
| Normalized Earnings Yield | 5.134 |